Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. - Wikidata - wikimedia - TriplyDB

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

http://www.wikidata.org/entity/Q34123137

about

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies Cardiovascular safety of anti-diabetic drugs Recent advances in managing and understanding diabetic nephropathy Diabetes Drugs and Cardiovascular Safety PPARs: Protectors or Opponents of Myocardial Function?Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects Is the cardiovascular system a therapeutic target for cannabidiol?Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies Treating the elderly diabetic patient: special considerations The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.After avandia: the use of antidiabetic drugs in patients with heart failure Peroxisome Proliferator-Activated Receptor- γ in Thyroid Autoimmunity Weight control and prevention of metabolic syndrome by green tea.Improvements in the Management of Diabetic Nephropathy Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in human hepatocytes Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study Risk of Bias in Systematic Reviews of Non-Randomized Studies of Adverse Cardiovascular Effects of Thiazolidinediones and Cyclooxygenase-2 Inhibitors: Application of a New Cochrane Risk of Bias Tool Study of Cardiovascular Health Outcomes in the Era of Claims Data: The Cardiovascular Health Study Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease.Evaluating Social Media Networks in Medicines Safety Surveillance: Two Case Studies Validation of methods for assessing cardiovascular disease using electronic health data in a cohort of Veterans with diabetes.Evaluating performance of electronic healthcare records and spontaneous reporting data in drug safety signal detection.Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis Potential and pitfalls of using large administrative claims data to study the safety of osteoporosis therapies.Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity.Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data.Differing effects of metformin on glycemic control by race-ethnicity.A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent.Rosiglitazone: a European regulatory perspective.Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study.Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-γ-knockout (CM-PGKO) mice.Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.Peroxisome proliferator-activated receptor γ agonists reduce cell proliferation and viability and increase apoptosis in systemic sclerosis fibroblasts.

P2860

Q22241134-4F441262-1AA4-44D5-8005-A71512300C60 Q24186319-EE3989C6-903C-40C7-BE74-8862096503B7 Q24201174-E205A200-F4F6-4E2C-A50F-36D15FB29520 Q24561401-943238AB-CA2E-48F7-9D61-B2C101C9D48C Q24632655-76572ABB-4092-42B9-8473-652A8BC0D251 Q26741082-F1FE2098-D934-4F46-A0DC-97A4CEE6E944 Q26745900-9D3DC355-AB0D-4CB8-9FFD-457E4C6873D0 Q26746085-01F829B9-5E87-4D70-84A0-2751645CD2CC Q26771753-2B13CBE5-78B5-43E4-8F87-9367FACCB39C Q26829098-605A1A85-7ED3-47C9-8346-7B9F90428AB1 Q26865370-98082AA4-9CD9-48D8-94DA-B15AB8DF3A9F Q26866958-A8650F00-49F0-4D57-B3AE-E36C2ED6EE5E Q26995176-A658C677-C228-4306-9814-8A6A91F583BC Q26999933-19CA7654-DCE5-4C18-8B21-2F8B9B421C4F Q27007027-4F293140-C4D5-4835-BACB-4F4B6CDA647D Q27021166-F1A5A714-BED8-4D0E-A257-EEBAF18965B0 Q27022369-A247059E-4A13-4EEB-8204-09A1B26C4860 Q27687558-BA7A7D22-1AAD-4FDA-B4DC-0BB240FC38A4 Q28080717-519114C7-F0A3-4F64-B7A4-E4D21D9DBEA0 Q28477796-0511C726-AD58-4400-8560-5818C3E88F5F Q28547367-747D871F-9308-42D5-8B3F-FC94CC5BA119 Q28551188-D3B8D356-1029-45A3-82EA-3BD701AFAE7A Q28601636-35D0A0B6-795D-4964-92D9-140CC62D409D Q28741419-251B1030-4240-465D-8B1E-8B98077CB93B Q30538243-7A769041-E762-43F5-A52C-56A5C8934055 Q30665207-480910E0-99D5-40F9-A06F-55D5B398A675 Q30740532-700161E6-A222-4835-B273-781D85B2BADD Q30876081-3EB101A3-7EA1-4087-B4B5-957090FFC380 Q30891396-CB5ADACA-E700-4FE1-8073-B0C2AB49DA40 Q33818302-9654E18C-E6FC-41E9-B5E6-6600AD8E15B0 Q33961458-D88EAF49-C18B-4773-9DD8-D258611EEF93 Q34065266-C3B97F52-2745-4653-B464-FE09C5325FC3 Q34099031-12A5FA1F-6BA2-4ADB-B360-38241DCB1788 Q34130997-341A82A2-046C-42D9-9E08-2E222BE938F4 Q34133971-BC633E3D-CF2F-49A3-82EA-734F8EA4AD98 Q34154718-59F8182F-074D-4906-AD2E-D6145F2694DB Q34202989-510EE353-6677-4690-A405-6C907C3088C4 Q34259900-3A4B9A0C-4790-45E6-970D-85D23AEEDA79 Q34315432-2AD3FD20-6620-4C59-9444-C21FB58EC0A6 Q34365179-54D1AA59-BC1D-47CC-AFF8-3684B4800E3E

P2860

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

http://www.wikidata.org/entity/Q34123137

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Risk of acute myocardial infar ...... rosiglitazone or pioglitazone.

@ast

Risk of acute myocardial infar ...... rosiglitazone or pioglitazone.

@en

Risk of acute myocardial infar ...... rosiglitazone or pioglitazone.

@nl

type

label

Risk of acute myocardial infar ...... rosiglitazone or pioglitazone.

@ast

Risk of acute myocardial infar ...... rosiglitazone or pioglitazone.

@en

Risk of acute myocardial infar ...... rosiglitazone or pioglitazone.

@nl

prefLabel

Risk of acute myocardial infar ...... rosiglitazone or pioglitazone.

@ast

Risk of acute myocardial infar ...... rosiglitazone or pioglitazone.

@en

Risk of acute myocardial infar ...... rosiglitazone or pioglitazone.

@nl

P1433

Q34123137-2D22068C-E3FC-42FE-865D-5FAD4A9ADA6D

P1476

Q34123137-C4756E06-808B-411C-BCC8-FC32960189AC

P2093

Q34123137-3639F33E-8779-4E4A-B55A-11148B062D62

Q34123137-3A49CD0A-FB7D-4A69-ACD7-A890819D733D

Q34123137-4117AD75-F408-48F3-8100-0F42641B0998

Q34123137-45D159C5-ABE6-4331-8A27-476DC8B844B5

Q34123137-9E842985-574D-4C50-9E77-E0993AD57311

Q34123137-9EFC733F-C175-4EC6-84B0-21036D33C74C

Q34123137-E7CE4C14-D67F-4B7D-9974-D206BF476038

P304

Q34123137-4BC9A2F6-7BD1-4BC0-8489-A1301CFB1B63

P31

Q34123137-B722516C-0017-4419-9CEA-C8CB85306234

P356

Q34123137-AC956B02-55CE-4C7B-B03D-FA546C567800

P407

Q34123137-BEBCC866-2F65-4773-9FF6-FADC98BDC2DB

P433

Q34123137-0DD61190-021E-4100-8F4D-DF529959424A

P478

Q34123137-3651314C-4015-4F9E-ACAA-3FB5F7BD2659

P577

Q34123137-29145C68-C294-4191-84CE-D16FF3BEDAF7

P5875

Q34123137-F934C96C-670C-44B0-9355-560F62B72FB1

P698

Q34123137-24838499-4AF8-4390-A646-D4BB471FD9C5

P921

Q34123137-6952E483-081D-4921-9450-E804B2502AC3

Q34123137-E3783281-3A2A-4472-AC69-6EB423AA376A

Q34123137-ED0DB37B-18FA-4BD8-85DF-4AE73A39B6BC

P356

P1433

Journal of the American Medical Association

P1476

Risk of acute myocardial infar ...... rosiglitazone or pioglitazone.

@en

P2093

Christopher Sholley

http://www.w3.org/2001/XMLSchema#string

Christopher Worrall

http://www.w3.org/2001/XMLSchema#string

David J Graham

http://www.w3.org/2001/XMLSchema#string

Farzana Ali

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Kelman

http://www.w3.org/2001/XMLSchema#string

Rita Ouellet-Hellstrom

http://www.w3.org/2001/XMLSchema#string

Thomas E MaCurdy

http://www.w3.org/2001/XMLSchema#string

P304

411-418

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.2010.920

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

304

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44806574

http://www.w3.org/2001/XMLSchema#string

P698

20584880

http://www.w3.org/2001/XMLSchema#string

P921